The most common side effects observed were the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea. The FDA label for<unk>  includes a warning for increased risk of infection, including serious and potentially fatal infections – such as potential reactivation of hepatitis B and tuberculosis. Other warnings and precautions for<unk>  include elevated liver enzymes, decreased neutrophil counts and hypersensitivity reactions.
Satralizumab
Caplacizumab
Brolucizumab
Natalizumab
Ixekizumab
Tocilizumab
Benralizumab
Ravulizumab